Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients

European Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2003, Pages 271-275

  Fogari, Roberto ^a   Preti, Paola ^a   Lazzari, Pierangelo ^a   Corradi, Luca ^a   Zoppi, Annalisa ^a   Fogari, Elena ^a   Mugellini, Amedeo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Benazepril; Fibrinolysis

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; SINGLE-BLIND METHOD; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0041911346     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0621-3     Document Type: Article

References (30)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (1997) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446
2. WHO/ISH Guidelines Committee (1999) 1999 World Health Organization/International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183
3. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al (1988) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-1762
4. Messerli FH, Grossman E, Goldbourt U (2001) Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 14:12S-16S
5. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksis N, Nieto FJ, Rasmussen ML, Wu KK (1999) Prospective studies of markers of hemostatic function with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Circulation 100:736-742
6. Held C, Hjemdahl P, Hakan Wallen N, Bjorkander I, Forslund L, Wiman B, Rehnqvist N (2000) Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study, the angina prognosis study in Stockholm. Atherosclerosis 148:179-188
7. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D (2000) Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 101:264-269
8. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singher DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW (2000) Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offsprings Study. JAMA 283:221-228
9. Lottermoser K, Weisser B, Hertfelder HJ, Wostmann B, Vetter H, Dusing R (1998) Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 11:378-384
10. Pedersen OD, Gram J, Bagger H, Keller N, Jespersen J (1994) Regulation of tissue-type plasminogen activator inhibitor type-1 in patients with ischemic heart disease: possible unfavourable effect of diuretics. Coron Artery Dis 5:617-623
11. Wright RA, Perrie AN, Stenhouse F, Alberti KG, Riemersma RA, Mac Gregor IR, Boon NA (1994) The long-term effect of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischemic heart disease. Eur J Clin Pharmacol 46:279-282
12. Gleerup G, Winther K (1991) Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 4:168S-171S
13. Vaughan DE, Rouleau JL, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 96:442-447
14. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A (1999) Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 137:1094-1099
15. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, Derosa G (2002) Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 15:316-320
16. Fogari R, Zoppi A, Preti P, Fogari E, Malamani GD, Mugellini A (2001) Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive post-menopausal women. Am J Hypertens 14:921-926
17. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 281:1039-1057
18. Kluft C, Jie AFH, Rijken DC, Verheijen JH (1989) Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fasting acting inhibitor (PAI-1). Thromb Haemost 59:329-332
19. Randy M, Sundell IB, Nilssan TK (1989) Blood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62:917-922
20. Eriksson E, Tengborn L, Risberg B (1989) The effect of various anticoagulant/antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 61:511-516
21. Wiman B, Mellbring G, Randy M (1983) Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 127:279-288
22. Chmielewska J, Randy M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31:427-436
23. Senn SJ (1993) Crossover trials in clinical research. John Wiley, New York, pp 38-46
24. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE (1993) Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 87:1969-1973
25. Feener EP, Northrup JM, Aiello LP, King GL (1995) Angiotensin II induces plasminogen activator inhibitor 1 and 2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353-1362
26. Vaughan DE, Lazos A, Tong K (1995) Angiotensin II regulates the expression of plasminogen activator inhibitor 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95:995-1001
27. Brown NJ, Nadeau J, Vaughan DE (1997) Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 77:522-525
28. Juhan-Vague I, Alessi MC (1997) PAI-1,obesity,insulin resistance and risk of cardiovascular events. Thromb Haemost 78:656-660
29. Vuorinen-Markkala H, Yki-Jarvien H (1995) Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 44:85-89
30. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, Lusardi P (1998) ACE-inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 32:616-620